Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the UK Cystic Fibrosis Gene Therapy Consortium, which is dedicated to the search for effective gene therapy for cystic fibrosis patients.
Subscribe to our email newsletter
Under the terms of the agreement, VGX will provide multiple batches of a Cystic fibrosis transmembrane conductance regulator (CFTR) product to support clinical studies planned to run through 2010. If all options are exercised, several hundred grams of plasmid DNA will be provided, making this agreement one of the largest contracts for non-viral gene therapy products ever undertaken.
Deborah Gill, Consortium’s lead investigator, said: “Our CpG-free product, utilizing technology developed by Cayla-InvivoGen, presented some unique challenges for large-scale production, but the Team at VGX used their vast expertise in producing non-viral products to meet our demanding timelines.”